A phase 2 trial of enGene's detalimogene voraplasmid in non-muscle invasive bladder cancer (NMIBC) has delivered a positive result, setting it on course for a filing with the FDA next year. The LEGEND ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback